Hycor Biomedical

Hycor Biomedical is an American biomedical company focused on the manufacture and supply of in vitro diagnostic products used primarily for blood-based allergy testing. The company was founded in 1981 by Steve Gorlin in Garden Grove, California, where it remains headquartered. Its business is centered on laboratory systems and reagents that help healthcare providers and clinical laboratories measure allergic sensitization from blood samples rather than relying exclusively on skin-based procedures. The company serves a specialized segment of clinical diagnostics. Allergy evaluation commonly includes skin-prick testing, in which a patient is exposed to an allergen and the resulting skin response is observed. In vitro testing provides an alternative approach in which a blood sample is analyzed in a laboratory. This approach can be useful when clinicians want to reduce the risk of provoking a substantial reaction, or when testing younger patients and other individuals for whom skin testing may be less suitable. Hycor's products are therefore positioned around laboratory efficiency, analytical sensitivity, sample conservation, and the standardization of allergy testing workflows. Hycor's principal product platforms include the NOVEOS Immunoanalyzer and the HYTEC 288 Plus EIA system. NOVEOS is described as a fully automated immunoanalysis platform using a small sample volume of approximately four microliters per test. Its technology combines paramagnetic microparticles as a solid phase with chemiluminescence and fluorescence methods, while its reagents are supplied in liquid, ready-to-use form. These characteristics are intended to support sensitive testing, simplify laboratory preparation, and reduce the amount of patient sample required. The platform is also presented as helping laboratories address interference-related issues in allergy testing. The HYTEC 288 Plus EIA system is an established enzyme immunoassay platform that continues to be used by laboratories in markets around the world. Together, the two systems represent Hycor's emphasis on dedicated allergy-testing infrastructure rather than a broad, general-purpose diagnostics portfolio. The company's offering includes the associated testing reagents and laboratory consumables needed to operate its systems, although the available reference material does not provide a complete catalog of products, regulatory clearances, revenue figures, or detailed market-by-market distribution information. Hycor has an international operating footprint. In addition to its California headquarters, it has an office in Amsterdam, Netherlands, supporting its presence in European and other international markets. A reference source estimates that the company holds approximately five percent of the allergy-testing market, but no date, methodology, or independently verifiable market-share report is supplied, so the figure should be treated as an estimate rather than a definitive current measurement. In early 2010, Hycor Biomedical was acquired by Linden Capital Partners, a private investment firm. The available material does not specify the transaction value, the exact closing date, or subsequent ownership changes. No public listing or stock ticker is identified. Hycor is best understood as a specialized, privately owned diagnostics brand serving clinical laboratories, allergy specialists, and healthcare systems that use in vitro methods for allergy assessment.

Hycor Biomedical was established in 1981 by Steve Gorlin in Garden Grove, California. From its founding, the company developed around the laboratory diagnosis of allergy, producing and supplying in vitro diagnostic systems for blood testing. This placed Hycor in a specialized area of biomedical diagnostics rather than in the broader market for general clinical chemistry, molecular testing, or medical devices. The company's underlying clinical context is the use of blood-based testing as an alternative or complement to skin-prick testing. Skin testing observes a patient's reaction after exposure to an allergen and can, in some cases, provoke a pronounced local or systemic response. In vitro testing moves the analytical step into the laboratory, allowing clinicians to use a blood sample to assess allergic sensitization. The approach has particular relevance when testing children or patients for whom direct allergen exposure may present practical or safety concerns. Hycor's product development has included both enzyme immunoassay infrastructure and more automated immunoanalysis. The HYTEC 288 Plus EIA system is an established platform that continues to serve laboratories internationally. The NOVEOS Immunoanalyzer represents a more automated approach, using approximately four microliters of sample per test, paramagnetic microparticles as a solid phase, and chemiluminescence and fluorescence methodologies. Its liquid, ready-to-use reagents are intended to reduce preparation requirements, while the system's design addresses the need for sensitive measurements and reduced sample consumption. The available material also associates NOVEOS with efforts to reduce interference issues in allergy testing. Hycor expanded beyond its United States base through an office in Amsterdam, Netherlands, giving the company a European presence alongside its Garden Grove headquarters. Reference material describes its products as being used by laboratories around the world. It also gives an estimated market share of approximately five percent in allergy testing, although the source does not provide a date or methodology for that estimate. A major ownership transition occurred in early 2010, when Linden Capital Partners acquired Hycor Biomedical. The reference material does not state the purchase price, whether the transaction involved a change in senior leadership, or whether the company subsequently became part of a larger operating group. There is also no supplied information about a public listing, revenue, employee count, or later acquisitions. The available record presents Hycor as an active, privately held specialist in allergy diagnostics. Its history is defined by a focused portfolio of laboratory instruments and reagents, an international distribution and office footprint, and continued development of automated blood-testing technology for allergy assessment.

• 2010

  Acquisition by Linden Capital Partners

  [1]Hycor Biomedicalen.wikipedia.org

  Linden Capital Partners acquired Hycor Biomedical in early 2010. Financial terms and subsequent ownership details are not provided in the available source.

• 1981

  Hycor Biomedical is founded

  [1]Hycor Biomedicalen.wikipedia.org

  Steve Gorlin founded Hycor Biomedical in Garden Grove, California, establishing the company as a specialist in in vitro allergy diagnostics.

A specialized in vitro allergy-diagnostics company emphasizing automated laboratory workflows, small sample volumes, sensitive analytical methods, and ready-to-use reagents.

• Automated in vitro allergy immunoanalysis

  NOVEOS Immunoanalyzer

  NOVEOS is Hycor's fully automated immunoanalyzer for blood-based allergy testing. The platform uses approximately four microliters of sample per test, paramagnetic microparticles as a solid phase, and chemiluminescence and fluorescence methodologies intended to support sensitive analysis. Its liquid, ready-to-use reagents are designed to simplify laboratory operation. The system is also presented as helping reduce interference issues and the amount of patient sample needed for testing.

• Enzyme immunoassay system

  HYTEC 288 Plus EIA system

  The HYTEC 288 Plus EIA system is an enzyme immunoassay platform used in allergy-testing laboratories. It is described as continuing to serve laboratories around the world, making it an established part of Hycor's diagnostic-system portfolio. The available source does not specify its original launch date, detailed throughput, assay menu, or regulatory status by market.

• 2010

  Acceptance of acquisition by Linden Capital PartnersM&A

  Background

  Hycor Biomedical operated as a specialist provider of in vitro allergy-testing products before being acquired by Linden Capital Partners in early 2010.

  Action taken

  Linden Capital Partners acquired the company. The available source does not identify the transaction value, detailed structure, or any management changes.

  Aftermath

  Hycor continued to be described as an active allergy-diagnostics company with operations in Garden Grove and an office in Amsterdam.

  Source

1. 1Hycor Biomedicalen.wikipedia.org